Tags : Tislelizumab


Chi-Med and BeiGene Collaborate to Evaluate the Combinations of Surufatinib

Shots: The two companies collaborated to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib and fruquintinib, with BeiGene’s tislelizumab against multiple solid tumor cancer indications in the US, EU, China and Australia. Both the companies will mutually supply drug and other support Tislelizumab is an anti PD-1 mAb, specifically designed to minimize binding to […]Read More


BeiGene Terminates its Worldwide Development and Commercialization Agreement with Celgene

Shots: BeiGene to receive $150M and regains WW rights for tislelizumab with their mutual termination of WW development & commercialization agreement with Celgene, following the pending acquisition of Celgene by BMS In Jul’17, BeiGene granted exclusive WW rights (Ex- Asia) of tislelizumab for solid tumor and retained global rights for hematology & solid tumor in […]Read More